# KEYNOTE-975 (NCT04210115)

> Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04210115
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)
- Interventions: pembrolizumab; placebo; cisplatin; 5-FU; radiotherapy; leucovorin; levoleucovorin; oxaliplatin
- Enrollment: 703
- Primary outcome: Event-free Survival (EFS)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 7
- YouTube: 5
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-975-nct04210115

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04210115", "email": "<work email>"}; the inbox owner confirms by the emailed link.